volume 2, issue 8, PS553 2007
DOI: 10.1097/01.jto.0000283622.38791.d3
View full text
|
|
Share

Abstract: Dual-agent chemotherapy is the current standard of care for patients with advanced non-small-cell lung cancer (NSCLC). While progress in patients' outcome has been made, significant variability in the efficacy and toxicity of anticancer drugs is observed in unselected populations of patients. Recent studies have shown promise for improved outcome if therapy is selected based on molecular tumor characteristics. Although resistance to gemcitabine and/or platinum are likely multifactorial, nucleotide metabolism …

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals